JP2023520333A5 - - Google Patents

Info

Publication number
JP2023520333A5
JP2023520333A5 JP2022557856A JP2022557856A JP2023520333A5 JP 2023520333 A5 JP2023520333 A5 JP 2023520333A5 JP 2022557856 A JP2022557856 A JP 2022557856A JP 2022557856 A JP2022557856 A JP 2022557856A JP 2023520333 A5 JP2023520333 A5 JP 2023520333A5
Authority
JP
Japan
Prior art keywords
cancer
alkyl
inhibitor
pharmaceutical product
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520333A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023752 external-priority patent/WO2021195128A1/en
Publication of JP2023520333A publication Critical patent/JP2023520333A/ja
Publication of JP2023520333A5 publication Critical patent/JP2023520333A5/ja
Pending legal-status Critical Current

Links

JP2022557856A 2020-03-24 2021-03-23 Eif4a阻害剤組み合わせ Pending JP2023520333A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993889P 2020-03-24 2020-03-24
US62/993,889 2020-03-24
PCT/US2021/023752 WO2021195128A1 (en) 2020-03-24 2021-03-23 Eif4a inhibitor combinations

Publications (2)

Publication Number Publication Date
JP2023520333A JP2023520333A (ja) 2023-05-17
JP2023520333A5 true JP2023520333A5 (cg-RX-API-DMAC7.html) 2024-04-03

Family

ID=77855108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557856A Pending JP2023520333A (ja) 2020-03-24 2021-03-23 Eif4a阻害剤組み合わせ

Country Status (8)

Country Link
US (1) US20210299111A1 (cg-RX-API-DMAC7.html)
EP (1) EP4125884A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023520333A (cg-RX-API-DMAC7.html)
KR (1) KR20230005175A (cg-RX-API-DMAC7.html)
CN (1) CN115996716A (cg-RX-API-DMAC7.html)
AU (1) AU2021244462A1 (cg-RX-API-DMAC7.html)
CA (1) CA3176264A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021195128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023030687A1 (en) 2021-09-01 2023-03-09 KHR Biotec GmbH Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
CN117982498A (zh) * 2022-11-01 2024-05-07 苏州开拓药业股份有限公司 一种含蛋白降解剂或抑制剂的组合物及其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2024254195A1 (en) * 2023-06-06 2024-12-12 Baylor University Methods for treating pancreatic cancer with a combination of des-methyl pateamine a and a class 1 hdac inhibitor
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
CN119351519B (zh) * 2024-10-21 2025-08-01 吉林大学 一种靶向隐孢子虫解旋酶的抗隐孢子虫小分子先导化合物
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
KR102934754B1 (ko) * 2015-11-25 2026-03-04 이펙터 테라퓨틱스, 인크. Eif4a-억제 화합물 및 이에 관련된 방법
CA3063563A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response

Similar Documents

Publication Publication Date Title
ES2911040T3 (es) Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2)
US20090041716A1 (en) Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
BR112020001695A2 (pt) compostos macrocíclicos e usos dos mesmos
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
WO2012143248A1 (en) Substituted pyrimidinyl-pyrroles active as kinase inhibitors
JP2023536164A5 (cg-RX-API-DMAC7.html)
JP5695200B2 (ja) 複素環アミノベルバミン誘導体、その調製方法及び使用
JP2020505395A5 (cg-RX-API-DMAC7.html)
US10947225B2 (en) Phosphotidylinositol 3-kinase inhibitors
JP2007515419A5 (cg-RX-API-DMAC7.html)
JP2016525104A5 (cg-RX-API-DMAC7.html)
US9714235B2 (en) Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
WO2022083657A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
US20160229857A1 (en) Substituted pyrrolo[2,3-d]dipyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
JP2017137323A (ja) 新規抗がん剤
CN110520118A (zh) 谷氨酰胺类似物的前药
CA3119036A1 (en) Anti-cancer activity of adamantane derivatives
WO2018117196A1 (ja) がん幹細胞を標的とする医薬
CA3195465A1 (en) Succinate and crystal form thereof as therapeutics
CN101265275B (zh) 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯
JP2022502378A5 (cg-RX-API-DMAC7.html)
JP2015531355A (ja) 腫瘍治療のための薬剤組成物及びその適用
US10093609B2 (en) TAK1 kinase inhibitors, compositions, and uses related thereto